Abstract:BACKGROUND:High Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arterial hypertension (PAH). No prior study has assessed the utility of HDL-C in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). OBJECTIVES:We aim to measure HDL-C levels in CTEPH patients and compare it to those in PAH patients and controls and determine HDL-C associations with markers of disease severity, hemodynamics and mortality in CTEPH. METHODS:We retrospectively included patients with CTEPH, identified from the Cleveland Clinic Pulmonary Hypertension Registry. All patients had right heart catheterization (RHC) and imaging studies consistent with CTEPH. We collected demographics, co-morbidities, baseline laboratory data including plasma HDL-C, six-minute walk test (6MWT), echocardiography and RHC. HDL-C levels were compared to a cohort of patients with cardiovascular risk factors and a previously published PAH cohort. RESULTS:HDL-C levels were available for 90 patients with CTEPH (age: 57.4±13.9 years; female 40%), 69 patients with PAH (age: 46.7±12.8 years; female 90%) and 254 control subjects (age: 56.7±13 years; female 48%). HDL-C levels in CTEPH patients were lower compared to controls and higher compared to PAH patients (median, IQR: CTEPH: 44, 34-57 mg/dl; PAH: 35.3, 29-39 mg/dl; Control: 49, 40-60 mg/dl; p < 0.01 for both pairwise comparisons). In CTEPH, higher HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). 57 patients with CTEPH underwent pulmonary thromboendarterectomy, higher HDL-C was associated with a larger decrement in postoperative pulmonary vascular resistance (PVR) (r = 0.37, p = 0.049). HDL-C was not associated with mortality or other markers of disease severity. CONCLUSIONS:HDL-C levels in CTEPH patients were lower compared to control subjects, but higher compared to PAH patients. Higher HDL-C in CTEPH was associated with less right ventricular dilation and greater decrement in postoperative PVR. These data suggest that HDL-C may be a useful marker of small vessel disease in CTEPH.

Association Study of Circulating Endothelial Cells and Clinical Outcome of Pulmonary Hypertension Secondary to Congenital Heart Disease

Levels of plasma endothelin and calcitonin gene-related peptide in children with congenital heart disease and pulmonary hypertension

Assessment of Reversibility in Pulmonary Hypertension Related to Congenital Heart Disease by Using Biomarkers and Clinical Features

A Combination of Clinical, Electrocardiographic, and Echocardiographic Parameters Predicts Pulmonary Hypertension Occurrence in Patients with End-Stage Renal Disease

Autologous Endothelial Progenitor Cells Transplantation for the Therapy of Primary Pulmonary Hypertension

The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease

Plasma Levels of High Density Lipoprotein Cholesterol and Outcomes in Chronic Thromboembolic Pulmonary Hypertension.

Comparative analysis of circulating endothelial progenitor cells and resected tissue-derived endothelial cells in chronic thromboembolic pulmonary hypertension (CTEPH).

Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

Echocardiographic Insights into Pulmonary Arterial Hypertension: the Advantage of Congenital Heart Disease Patients

Characteristic disease defects in circulating endothelial cells isolated from patients with pulmonary arterial hypertension

Hemodynamic Analysis Of Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: A Numerical Study Of Patient-Specific Models

The Alteration and Clinical Significance of Plasma Endothelin-1 in Patients with Congenital Heart Disease Accompanied by Secondary Pulmonary Hypertension

[End Tidal PCO(2) for Evaluation of Severity of Disease in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension].

Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases

Clinical usefulness of endothelial progenitor cells in predicting the efficacy of riociguat in chronic thromboembolic pulmonary hypertension

Changes in Complement Factor H-related Protein 2 in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease and Its Potential Clinical Significance

The predictive value of minute ventilation versus carbon dioxide production in pulmonary hypertension associated with left heart disease

Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study

Study of Angiotensinii Level Fluctuation in Patients with Congenital Heart Diseases Pre- and Post-Interventional Therapy

Differentially Expressed Genes and Pathways between Reversible and Irreversible Pulmonary Arterial Hypertension Associated with Congenital Heart Disease Investigated by Bioinformatics Analysis in Rat Model